India's government said on Thursday it has inked a deal with domestic vaccine maker Biological-E for 300 million COVID-19 vaccine doses for 15 billion rupees ($205.62 million), the first such order for unapproved shots.
The RBD protein sub-unit vaccine, which is currently undergoing phase-3 clinical trials, is likely to be available in the next few months, the health ministry said in a statement.
India inks deal with domestic vaccine maker Biological-E for 300M doses banglamirrornews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from banglamirrornews.com Daily Mail and Mail on Sunday newspapers.
Biological E partners with Canadian firm to manufacture mRNA vaccines in India
Biological E partners with Canadian firm to manufacture mRNA vaccines in India
02 June 2021 | News With a minimum production capacity of 600 million doses in 2022 and a target capacity of 1 billion doses
Image credit- shutterstock.com
Canadian firm Providence Therapeutics Holdings Inc. and Hyderabad-based Biological E have announced the execution of a term sheet, that sets forth the material terms for a definitive licensing and collaboration agreement. It also outlines the terms for sale by Providence of up to 30 million doses of Providence’s proprietary messenger RNA vaccine, PTX-COVID19-B, to Biological E and other End-buyers.